Leidos Biomedical Research, Inc.
Operating the Frederick National Laboratory for Cancer Research
A 25 year partnership in biomedical innovation
For more than 25 years, Leidos Biomedical Research has partnered with the National Cancer Institute (NCI) to operate Frederick National Laboratory for Cancer Research, the only National Laboratory focused exclusively on biomedical research.
Our work is dedicated to improving human health and enabling scientists to conduct investigator-initiated, hypothesis-driven research. Our team provides expertise in genetics, genomics, protein science, proteomics, bioinformatics, high-performance biomedical computing, and clinical operations. We provide scientific support to the NCI, the National Institute of Allergy and Infectious Diseases, and many more of the National Institutes of Health’s 27 institutes and centers, collaborating with intramural and extramural investigators to accelerate discovery and innovation in the biomedical sciences. Our focus is on cancer, HIV infection, and emerging infectious diseases such as COVID-19.
Our commitment to this unique partnership is on display through our work with government agencies, organization directorates and academic/extramural institutions that routinely come together to solve the world’s most critical biomedical challenges. We are proud of this partnership and the contributions we have made to advance biomedical research and health over the past 25 years.
Critical research for global public health challenges
Improving the drug development process
Our biomedical informaticists advance disease research through collaborations and integration of scientific data, advanced computing, and artificial intelligence to create a new pre-competitive platform for drug discovery.
Making therapies available faster and improving the ability to prevent and detect cancer
Our employees improve the ability to detect and prevent cancer through their programmatic work with precision medicine clinical trials, the NCI Patient-Derived Models Repository, and the NCI Genomic Data Commons.
Conducting data science and biomedical research in the global effort to combat COVID-19
Our employees facilitated randomized, placebo-controlled international clinical trials, pivoted the HPV Serology Lab to support COVID-19 serology, worked to explain genetic susceptibility to COVID-19, and leveraged the RAS Initiative compound libraries to screen for novel candidate agents to combat the disease. We also supported NCI in establishing the Serological Sciences Network, (SeroNet), the nation’s largest coordinated effort to study the immune response to COVID-19.
Improving understanding and integration of AIDS-associated virus research
Our researchers improve the diagnosis, prevention, and treatment of HIV infections, AIDS, and AIDS-related tumors associated with cancer viruses. Most recently, our team has participated in a clinical study on the effects of SARS-CoV-2 infections on HIV-1 viral loads on patients infected with both viruses. We’ve also collaborated with Uganda Virus Research Institute on a large SARS-CoV-2 population monitoring study on herpesvirus reactivation.
Advancing scientific insights of cancers driven by RAS mutations
One-third of human cancers are driven by mutations in the RAS family of genes. Our scientists investigate approaches to RAS-driven cancer from protein production to assay development. We facilitate an international RAS research community and contribute to the search for an effective RAS inhibitor.
World-class scientific talent
Our experts are committed to solving the world’s most critical public health challenges, driving scientific discoveries and biomedical advancements. Meet some of our Leidos Biomedical Research team!
Learn more about our work
Frederick National Laboratory is one of 18 national laboratories, and the only one dedicated to biomedical sciences. Our work creates a culture that empowers employees, sparks innovation, and addresses the most urgent challenges in biomedical research.